Tharimmune (NASDAQ:THAR) Issues Earnings Results

Tharimmune (NASDAQ:THAR) released its earnings results on Tuesday. The company reported ($2.02) earnings per share for the quarter, Zacks reports.

Tharimmune Stock Performance

Shares of NASDAQ THAR traded down $0.02 during midday trading on Thursday, hitting $1.42. The company’s stock had a trading volume of 3,157 shares, compared to its average volume of 353,464. The stock has a fifty day moving average price of $1.75 and a 200 day moving average price of $2.12. Tharimmune has a one year low of $1.28 and a one year high of $7.46.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Rodman & Renshaw initiated coverage on Tharimmune in a report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).